Citigroup Maintains Buy on Mirati Therapeutics, Lowers Price Target to $127

Citigroup analyst Yigal Nochomovitz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $208 to $127.

Citigroup analyst Yigal Nochomovitz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $208 to $127.

Total
0
Shares
Related Posts
Read More

Exclusive: Historic Importation Of THC Into The US Could Reshape Global Cannabis Supply Chain

This novel venture could reshape the foundations of the global medical cannabis supply by delivering alternative THC products to a DEA-approved Schedule 1 lab in the U.S and providing universities, researchers and pharmaceutical entities with an alternative to the University of Mississippi, which until very recently had been the sole legal supplier of THC active pharmaceutical in

BGXX